Table 3 Per-protocol primary endpoint analysis of treatment responses in cases with Plasmodium falciparum or Plasmodium. vivax for PCR-corrected malaria
AL | DHA-PPQ | Total | P-value | |
|---|---|---|---|---|
P. falciparum assessed at day 28, n | 110 | 138 | 248 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 110 (100) [95.8–100] | 138 (100) [96.6–100] | 248 (100) | – |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 0 | 0 | 0 | – |
Late parasitological failure, % | 0 | 0 | 0 | – |
P. falciparum assessed at day 42, n | 106 | 135 | 241 | |
Adequate clinical and parasitological response, n (%) [95% CI] | 104 (98.1) [92–99.7] | 135 (100) [96.6–100] | 239 (99.2) | − 0.11 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 0 | 0 | 0 | – |
Late parasitological failure, % | 1.9 | 0 | 0.8 | – |
P. vivax assessed day 28, n | 23 | 41 | 64 | – |
Adequate clinical and parasitological response, n (%) [95% CI] | 22 (95.7) [76.03–99.8] | 41 (100) [89.3–100] | 63 (98.4) | 0.18 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 0 | 0 | 0 | – |
Late parasitological failure, % | 4.3 | 0 | 1.6 | – |
P. vivax assessed day 42, n | 19 | 39 | 58 | – |
Adequate clinical and parasitological response, n (%) [95% CI] | 15 (78.9) [53.9–93.03] | 36 (92.3) [78.03–98.0] | 51 (87.9) | 0.14 |
Early treatment failure, % | 0 | 0 | 0 | – |
Late clinical failure, % | 5.3 | 0 | 1.7 | – |
Late parasitological failure, % | 15.8 | 7.7 | 10.3 | – |